PK and PD Responses to Oral L-Citrulline in Patients With Sickle Cell Disease
NCT00343954 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12
Last updated 2006-06-23
Summary
To evaluate PK and PD responses to L-citrulline given orally for four weeks to patients with sickle cell disease who are otherwise healthy.
Conditions
Interventions
- DRUG
-
L-citrulline tablets, 1000 mg
Sponsors & Collaborators
-
Angiogenix
lead INDUSTRY
Principal Investigators
-
Lakshmanam Krishnamurti, MD · Children's Hospital of Pittsburgh, Univ. of Pittsburgh Medical Center
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 10 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- United States
Study Locations
More Related Trials
-
L-Arginine and Sickle Cell Disease
NCT01142219 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate Safety, Pharmacokinetic, and Biological Activity of INCB059872 in Subjects With Sickle Cell Disease
NCT03132324 ·Status: TERMINATED ·Phase: PHASE1
-
Effectiveness of Arginine as a Treatment for Sickle Cell Anemia
NCT00513617 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of Orally Administered NUV001 Nutraceutical Supplement in Sickle Cell Disease Patients
NCT05791591 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Codeine in Sickle Cell Disease
NCT00174538 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
The Role of Endothelin-1 in Sickle Cell Disease
NCT02712346 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia
NCT01179217 ·Status: COMPLETED ·Phase: PHASE3
-
Arginine Treatment of Acute Chest Syndrome (Pneumonia) in Sickle Cell Disease Patients
NCT00029731 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at Increased Risk for Primary Stroke
NCT05953584 ·Status: RECRUITING ·Phase: PHASE2
-
L-Glutamine Therapy for Sickle Cell Anemia and Sickle ß0 Thalassemia
NCT00125788 ·Status: COMPLETED ·Phase: PHASE2
-
Hydroxyurea to Prevent Brain Injury in Sickle Cell Disease
NCT01389024 ·Status: COMPLETED ·Phase: PHASE2
-
Hydoxycarbamide and L-Carnitine Therapy in Sickle Cell Anemia
NCT05081349 ·Status: COMPLETED ·Phase: PHASE4
-
Dose-Escalation Study of SCD-101 in Sickle Cell Disease
NCT02380079 ·Status: UNKNOWN ·Phase: PHASE1
-
L-Glutamine Therapy for Sickle Cell Anemia
NCT00586209 ·Status: TERMINATED ·Phase: PHASE2
-
Arginine Therapy for Sickle Cell Disease Pain
NCT02536170 ·Status: COMPLETED ·Phase: PHASE2
-
Long Term Effects of Hydroxyurea Therapy in Children With Sickle Cell Disease
NCT00305175 ·Status: COMPLETED
-
Assessment of Tolerance of Mobilizing Peripheral Hematopoietic Stem Cells by Plerixafor in Sickle Cell Patients
NCT02212535 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of Varespladib Infusion in Subjects With Sickle Cell Disease.
NCT01522196 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease
NCT01476696 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises
NCT01895361 ·Status: COMPLETED ·Phase: PHASE2
-
An Assessment of Prasugrel on Healthy Adults and Sickle Cell Adults
NCT01178099 ·Status: COMPLETED ·Phase: PHASE1
-
TRF-1101 Assessment in Sickle Cell Disease
NCT00773890 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Penicillin Prophylaxis in Sickle Cell Disease (PROPS)
NCT00000585 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of the Effect of IW-1701 (Olinciguat), a Stimulator of Soluble Guanylate Cyclase (sGC), on Patients With Sickle Cell Disease (SCD)
NCT03285178 ·Status: COMPLETED ·Phase: PHASE2
-
Assessment of Opioid Analgesia in Sickle Cell
NCT00513864 ·Status: WITHDRAWN ·Phase: PHASE4